Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $234
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Overweight and raises the price target from $225 to $234.